secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001549595-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg
--------------------------------------------------------------------------------

- FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.
- Bexobrutideg Phase 1 in r/r CLL: 83% ORR, median PFS 22.1 months; DAYBreak pivotal Phase 2 initiated at 600 mg.
- Completed $250M stock offering in Oct 2025; cash, cash equivalents & marketable securities $592.9M.
- Appointed Roger Dansey to Board; Phase 3 randomized trial vs pirtobrutinib expected H1 2026.
- Preclinical IRAK4 degrader GS-6791 data presented; Phase 1 HV study ongoing; autoimmune IND planned 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/0001549595-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/nrix-20260128.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer